Cellectar Biosciences Inc
Research Cellectar Biosciences Inc (CLRB) on Bullrun: market cap USD 20.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLRB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 20.96M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.65M
- Free cash flow-USD 4.85M
Valuation Snapshot
latest market cap is USD 20.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 21.79M | -USD 23.12M | n/a | -8.35 | USD 13.20M | USD 409.59K | USD 8.54M |
| FY2024 | USD 0 | -USD 44.58M | -USD 47.69M | n/a | -41.89 | USD 23.29M | USD 494.00K | USD 14.29M |
| FY2023 | USD 0 | -USD 37.98M | -USD 33.24M | n/a | -3.5 | USD 9.56M | USD 552.98K | -USD 15.16M |
| FY2022 | n/a | -USD 31.79M | -USD 25.45M | n/a | -4.51 | USD 19.87M | USD 236.06K | USD 8.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 20.96M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.51M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.82M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 34.04M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 16.05M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 40.33M | n/a | n/a | n/a |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cellectar Biosciences Inc's market cap?
Cellectar Biosciences Inc's market capitalization is USD 20.96M.
What does Cellectar Biosciences Inc do?
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.